February 14, 2022 7:51am
Uncertainty rules, this is not a good time to be adding risk exposure
Sector earnings: Applied Genetic Technologies (AGTC)
Pre-open indications: I am passing on predilections today but, not forgetting the pimp/pump/promote of Biostage (BSTG)
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Only the facts … I ask questions and note the probabilities
Dow futures are DOWN -0.10% (-36 points), S&P futures are DOWN -0.07% (-4.25 points) and NASDAQ futures are DOWN -0.16% (-23 points)
Stock futures were lower early Monday morning as investors continued to monitor the Ukraine and Russia and impact of upcoming Fed rate hikes,
European markets tumbled deep into the red as oil prices rocketed amid concern about a possible Russian invasion of Ukraine.
Asia-Pacific markets fell overnight, with the Nikkei more than 2.2% down in Japan, the Hang Seng falling 1.4% and the Shanghai Composite closing 1% lower.
Henry’omics:
Markets are preparing for the heightened risk of a Russian invasion in the Ukraine, and it’s driving uncertainty and volatility.
On Friday, the Dow tumbled 503.53 points, or -1.43%. The S&P 500 fell -85.44 points or -1.9% and the Nasdaq dived -394.49 points or -2.78%.
If you didn’t remember what happen at Friday’s close, you won’t be prepared for today’s session,
RegMed Investors’ (RMi) closing bell: “the week ends with an empty bottle of cell and gene therapy advancements. Increased concerns about Russia taking military action against Ukraine.” … https://www.regmedinvestors.com/articles/12298
Ebb and flow –
- February stats: 5 negative and 4 positive closes
- January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
Probabilities/ Potentials pre-open share pricing indication moves:
I feel a negative bias in anything:
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed down on Friday -$0.02 with 1,739 shares traded after Thursday’s +$0.60 to $4.58 with 2,841 shares traded, Wednesday’s -$0.61 with 4,030 shares traded, Tuesday’s +$0.05 to $4.59 with 1,293 shares traded and Monday’s +$0.55 with 2,311 shares traded,
The previous Friday’s +$0.22 with 305 shares traded, Thursday’s flat (-$0.00) with 3 shares traded, Wednesday’s -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares traded, Monday’s flat with 11 shares traded,
And the preceding Friday’s +$0.05 to $3.90 with 3,362 shares traded, Thursday’s +$0.24 to $3.85 with 10,073 shares traded.
- WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position overseen?
- Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering- they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: The stock market rally sold off hard to end last week, with the major indexes breaking below key levels.
With the cell and gene therapy sector reeling, it's not a good environment for buying stocks.
I continue my skittishness regarding earnings’ reporting and the volatility in trading that usually precedes and follows releases.
- Two (2) earnings reports (ALNY & RARE) so far, with misses in estimates and one (1) on revenue, today (Monday) is AGTC’s turn.
Reiterating, “the cell and gene therapy sector’s relative valuation metrics suggest earnings reports are about to hit and I believe, hard.”
Investors have to recognize what kind of market we are in – VOLATILE with LOW VOLUME. Which gives us reasons to be cautious.
Earnings’ reporting:
- Applied Genetic Technologies (AGTC) Today
- AxoGen AXGN) – 2/22, Tuesday, 2/22
- Sage Therapeutics (SAGE), Thursday, 2/24
- Ionis Pharmaceuticals (IONS), Thursday, 2/24
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q1/22 waiting for Q4 and FY21 numbers”.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
